Skip to content
  • About
  • Events
  • Advocacy
  • Coalitions
  • About
  • Events
  • Advocacy
  • Coalitions
Facebook-square Icon-twitter-x Youtube
  • About
  • Events
  • Advocacy
  • Coalitions
  • About
  • Events
  • Advocacy
  • Coalitions

Category: Blog

Physicians Urge Protection for Cancer Care in New IfPA White Paper

Once upon a time, the gravity of cancer ensured its patients access to life-saving treatments.

Exchange Plans Disrupt Rx Access for Rare Disease Patients, New Study Reveals

New research suggests that rare disease patients purchasing health coverage through a state or federal exchange face an all-too-common challenge: access to so-called orphan drugs.

Health Care Partnership Could Help Access to Real World Data

Real world data could improve patient care and result in more targeted pharmaceutical innovation, a new Morning Consult blog post suggests.

Webinar Features States’ Fights against Discriminatory Cost-sharing

As concerns about insurers’ discriminatory practices against chronic disease patients grow, several states have taken steps to limit coverage models that require excessive cost-sharing.

Online Health Resources Bolster Physician-Patient Relationship

Physicians know that having informed patients can help maximize the physician-patient relationship.

Innovation Goes Interactive with New Data Hub

Infographics, slide shows and interactive timelines now bring the latest information on emerging medical therapies together in one place: PhRMA’s new Innovation Hub.

IfPA Urges Caution in New “Indication Extrapolation” Policy Brief

The Food and Drug Administration’s approval process ensures safety and efficacy for each medical therapy and each indication approved.

New AfPA Video Examines Pain Management Policy

How can policy limit prescription pain pill abuse without impeding medical access for patients with legitimate pain?

Rare Disorders Organization Stresses Testing, Transparency on Biosimilars

Maximizing biologic medicine’s potential for rare disease patients means observing needed safety precautions.

Hydrocodone Reclassification Alters Pain Treatment Rules

In the newest move to reduce prescription opioid abuse, the U.S. Drug Enforcement Administration has reassigned hydrocodone combination products (HCPs) to Controlled Substance Schedule II.

← Previous
Next →
  • STATE CHAPTERS
  • GLOBAL AFPA
  • INSTITUTE FOR PATIENT ACCESS
  • CONTACT US
  • STATE CHAPTERS
  • GLOBAL AFPA
  • INSTITUTE FOR PATIENT ACCESS
  • CONTACT US
Subscribe to our newsletter

© 2024, Alliance for Patient Access.

Website Management provided by Genacom
2020 K Street NW, Suite 505 Washington, DC 20006
[email protected]
(202) 951-7097
Facebook-square Icon-twitter-x Youtube